Introduction
About one third of epilepsy patients do not respond to antiepileptic drugs (AEDs). 1 Some studies showed that over expression of P-glycoprotein (P-gp) in brain tissue contributes to the resistance to AEDs. 2 P-gp is an efflux transporter that limits the cellular uptake levels of various drugs in intestine, brain, and other tissues. 3 It is encoded by the ABC subfamily B member 1 (ABCB1) transporter gene. The human ABCB1 gene is located at chromosome 7p21, composed of 29 exons (http:// www.ncbi.nlm.nih.gov). The C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642) loci are the most commonly studied genetic variants in the ABCB1 gene. C1236T and C3435T polymorphisms are synonymous loci which alter the GGC codon to GGT (Gly412Gly) and the ATC codon to ATT (Ile1145Ile), respectively. However, the ABCB1 G2677T/A polymorphism is a non-synonymous locus resulting in amino acid exchanges (Ala893Ser or Ala893Thr). Among these three loci, C3435T polymorphism has received more attention as a critical variant in AEDs resistance. [4] [5] [6] [7] Several genetic studies have attempted to link the ABCB1 gene common genetic variants to the resistance to AEDs, but the results have been conflicting. Our meta-analysis involving 6755 Asian and Caucasian patients did not confirm this association in the total study population or in the ethnic subgroups. [8] [9] [10] [11] Therefore, it was suggested that controversy between the studies may be caused by the effect of some confounders such as ethnicity and polytherapy. 8 It is proposed that linkage disequilibrium (LD) of the silent C3435T with other ABCB1 variants in a haplotype block may link with resistance to AEDs. 12 Haplotype and LD patterns are population specific, most probably shaped by evolutionary forces such as natural selection in ancestral populations in various geographical regions. Diversity in the haplotype block structures and LD patterns is high in European and East Asian populations. This diversity may cause crucial changes in the complex interaction of genetic and environmental factors in producing some phenotypes such as susceptibility to disease and response to pharmacological agents. [13] [14] [15] Therefore, some studies examined
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the association of the ABCB1 haplotype derived from C1236T, G2677T/A, and C3435T in response to AEDs in different populations, but results were inconsistent. 9, 11, [16] [17] [18] [19] [20] [21] [22] [23] [24] Evidence showed that the ABCB1 gene expression is under the control of pregnane X receptor (PXR). The PXR is activated by a broad range of compounds including steroids, antibiotics, and drugs. Once activated, it binds cognate transcription factor response elements which are located in the promoters of target genes, thereby regulating expression of the involved genes in the metabolism and transport of xenobiotics including the CYP3A family and ABCB1 gene. Because of the important role of PXR in regulation of ABCB1 gene, several studies reasoned that variation in the PXR gene might contribute to response to treatment. Some reports showed a strong association between PXR G7635A (rs6785049) polymorphism with susceptibility to inflammatory bowel disease and Crohn's disease as well as response to treatment in the renal transplant recipients. [25] [26] [27] [28] Therefore, in this study, we addressed the question of whether ABCB1 C1236T, G2677T/A, and C3435T and PXR G7635A polymorphisms are associated with the response to treatment in the Malaysian population with epilepsy, as well as in the Chinese, Indian, and Malay ethnic subgroups.
Methods

Subjects
The present study is part of an ongoing multicentre cooperation between the University of Malaya Medical Centre and the National University of Malaysia Medical Centre. The study protocol was approved by the Ethics Committees of both centres. A total of 685 patients with epilepsy who were on carbamazepine (CBZ) or sodium valproate (VPA) monotherapy were recruited from the epilepsy clinics and diagnosed by neurologists who were blinded to the genotype data. Seizures and etiology of epilepsy were classified according to the International League Against Epilepsy guidelines. 29 On the basis of new definitions of treatment outcomes, 30 drug responsiveness was defined as being completely seizure free for at least 1 year during treatment with either CBZ or VPA monotherapy, and drug resistance was defined as the occurrence of seizures over a period of 1 year during treatment with either CBZ or VPA monotherapy at maximally tolerated therapeutic dosages. Epilepsy patients of Chinese, Indian, and Malay ethnicities were eligible for inclusion if they were on monotherapy of either CBZ or VPA for at least 1 year. Exclusion criteria included severe adverse drug reactions, poor compliance with CBZ or VPA, being on other AED monotherapy such as phenytoin and lamotrigine (LTG) or on polytherapy with various AEDs, unreliable record of seizure frequency, significant psychiatric comorbidity, history of pseudoseizures, alcohol or drug abuse, and presence of progressive or degenerative neurological or systemic disorders. Written informed consent was given by all patients or by their guardians in the case of a child. A standardized extraction template was administered to collect demographic details and information on seizure types and frequency, medical history, concomitant drug history, and relevant family history from the records.
Genotyping
Genomic DNA was extracted from either whole blood or buccal swabs by using standard methods. The ABCB1 (C1236T, G2677T/A, C3435T) and PXR (G7635A) polymorphisms were genotyped by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). 28, 31, 32 PCR and RFLP products were analyzed by electrophoresis in 2% agarose gels. The results of PCR-RFLP were confirmed through DNA sequencing of a random selection of samples (5%) by using the ABI Prism 3130 Genetic Analyzer (Applied Biosystems, USA) and ABI Prism Big Dye Terminator v3.1 cycle sequencing kit.
Statistical methods
All values were presented either as the mean AE standard deviation for continuous data or as frequency for categorical data. The ages at study and onset of epilepsy were non-normally distributed variables, examined by the Kolmogorov-Smirnov test. Therefore, the frequency of these two variables was compared for drug-resistant and drug-responsive patients by the non-parametric Mann-Whitney U test or the Kruskal-Wallis rank sum test. Comparison of distribution of ethnicity, etiology of epilepsy, and seizure type in overall patients, irrespective of response to CBZ or VPA, was performed by binary logistic regression test.
The alternative genetic models for C1236 and C3435T polymorphisms included alleles (C vs. T) and genotypes for codominant (C/C vs. T/T and C/T vs. T/T), dominant (C/C + C/T vs. T/T), and recessive (C/C vs. C/T + T/T) models. For simplification of the analysis of genetic models of the triallelic G2677T/A variant, the A allele was included with the T allele. The alternative genetic models for the G2677T polymorphism included alleles (G vs. T) and genotypes for co-dominant (G/G vs. T/T and G/T vs. T/T), dominant (G/G + G/T vs. T/T), and recessive (G/G vs. G/T + T/T) models.
Alternative genetic models for PXR G7635A locus included codominant (G/G vs. A/A and G/A vs. A/A), dominant (G/G + G/A vs. A/ A), and recessive (G/G vs. G/A + A/A). A goodness-of-fit x
2 test with one degree of freedom was applied to test Hardy-Weinberg equilibrium (HWE) of the three polymorphisms; p < 0.05 indicated a lack of agreement with HWE. Association of alleles and genotypes with response to CBZ or VPA monotherapy was calculated with binary logistic regression, adjusted for ethnicity, drug type, gender, age at recruitment, onset age of epilepsy, seizure type, and etiology of epilepsy. Haplotype and LD analysis for the three ABCB1 polymorphisms was performed with the Haploview 4.2 program and corrected for multiple testing by using 100,000 permutations for individual locus and haplotypes. Bonferroni's method was used for correction of multiple comparisons. Two-sided tests of statistical significance were used to determine statistically significant p values (p < 0.05) with the SPSS software package (ver. 15.0; SPSS, Chicago, IL, USA).
Results
Patient characteristics
A total of 685 epilepsy patients who were on CBZ or VPA monotherapy participated in this study. Of these 685 patients, 277 (40.4%), 160 (23.4%), and 248 (36.2%) were Chinese, Indians, and Malays, respectively. About 62% of the recruited patients were on monotherapy treatment with VPA. The demographic characteristics of 323 (47%) drug-resistant and 362 (53%) drug-responsive patients are shown in Table 1 . The distribution of ages at study did not significantly differ between drug-resistant and drug-responsive patients in total or among the Chinese, Indian, and Malay patients. Onset of epilepsy in the overall population as well as in Chinese drug-resistant patients was significantly earlier than the drug-responsive patients (p = 0.02 and p = 0.04, respectively). Males were over-represented (p = 0. 013), but this was not significantly different between drug-resistant and drug-responsive patients or in each ethnic subgroup. Partial seizure was significantly more common among drug-resistant patients than drugresponsive group in the overall (p = 0.003) and in the Malay subgroup (p < 0.001). Moreover, symptomatic (39%) and cryptogenic (36%) epilepsy were also more often diagnosed in the patients. Symptomatic (p < 0.001) and cryptogenic (p = 0.007) epilepsy were significantly more common in drug-resistant than drug-responsive patients in the overall patients. Similar results were obtained in the Malays (p < 0.01) but a marginal significance was observed in the Chinese patients (p = 0.05) with symptomatic epilepsy. Table 2 lists the allele and genotype frequencies of the ABCB1 and PXR polymorphisms of the drug-resistant and drug-responsive patients. In this study, the C1236 allele was less common than the alternative allele in the overall (43%) or in the Chinese (42.5), Indians (44.5), and Malays (41.5). In the Chinese (52%) and Malay (53%) patients, the G2677 allele was more frequent than the minor allele while it was less frequent in the Indians (41%) than the 2677T allele. The C3435 and G7635 alleles were more frequent than the alternative alleles in the overall (60.5%) and in each ethnicity (Chinese 60%, Indians 54.5%, and Malays 65.5%). The ORs adjusted for ethnicity, gender, age at the recruitment, age at the onset of epilepsy, seizure type, drug type, and epilepsy etiology were calculated for alternative genetic models.
Allele and genotype associations of ABCB1 and PXR polymorphisms with response to drug treatment
ABCB1 C1236 was slightly more frequent in the Chinese (43%) and Malay (44%) drug-resistant patients as compared to the drugresponsive patients (43 and 44%, respectively). Similarly, ABCB1 G2677 allele was more frequent in the Chinese (55%) and Malay (55%) drug-resistance than drug-responsive patients (49 and 51%, respectively). Unlike the Chinese subgroup, frequency of the ABCB1 C3435 allele in the Indian (58%) and Malay (60%) drugresistant patients was more than drug-responsive patients (48 and 58%, respectively). Finally, unlike the Indian subgroup, frequency of the PXR G7635 allele in the Chinese (58%) and Malay (64%) drugresistant was less than drug-responsive patients (62 and 67%, respectively). In the Chinese, Indian, and Malay subgroups, no significant association was observed between C1236 [adjusted OR 0.89, 95% CI 0.61-1. The genotype distribution of all polymorphisms in both drugresistant and drug-responsive patients in the total group or in each ethnic subgroup was consistent with HWE. There was no significant association between the ABCB1 (C1236T, G2677T, C3435T) and PXR (G7635A) genotypes with response to drug treatment in the total sample or in the Chinese and Malay subgroups under alternative genetic models (Table 3) . However, the ABCB1 C3435T locus in the Indian subgroup showed a significant association with response to treatment under recessive model (adjusted OR 0.38, 95% CI 0.16-0.86, p = 0.02). After correction of multiple comparisons with Bonferroni's method, this significant association was lost (0.05/4). Table 4 lists the eight possible haplotypes of ABCB1 polymorphisms in the drug-resistant and drug-responsive patients. Overall, the TTT (22%) and the CGC haplotypes (20%) were more (12) 14 (14) 0.14 0.98 (0.96-1.00)
Haplotype association of ABCB1 and PXR polymorphisms with response to treatment
14 (15) 16 ( frequent than other ABCB1 gene haplotypes. Similar results for the TTT and CGC haplotypes were observed in the Chinese (20 and 16%, respectively) and Malay subgroups (23 and 22%, respectively), but for only the TTT haplotype in the Indian subgroup (25%). Of the 27 possible diplotypes in total patients, CGC-TTT and TTT-TTT were most frequent among diplotypes. However, in the Chinese patients, TGC-TTT frequency was higher (14%) than other diplotypes. Haplotypes and diplotypes in the total patients with frequency of above 5% were encountered for association analysis. The association between ABCB1 haplotypes and response to treatment was not significant in the overall or in the Chinese, but it was significant for the TTC haplotype in the Indian and Malay subgroups (Table 4 ). However, after using 100,000 permutation test and Bonferroni's correction for multiple comparisons, these associations were lost (p = 0.01 and p = 0.02 < 0.05/8, respectively). No significant association was observed between ABCB1 diplotypes and response to treatment in the overall or in each ethnic subgroup. There was no strong LD between C1236T/ G2677T, G2677T/C3435T, and C1236T/C3435T polymorphisms in the overall or in each ethnic subgroup. No significant association of ABCB1 and XPR gene interaction with response to treatment was identified in the overall (cross-validation consistency = 10/10, testing accuracy = 53.3%, p = 0.93) as well as in Chinese (testing accuracy = 51.1%, p = 0.70), Indian (testing accuracy = 57.7%, p = 0.42), and Malay (testing accuracy = 51.2%, p = 0.94) ethnic subgroups.
Discussion
In the present study, we hypothesized that a relationship exists between ABCB1 and PXR polymorphisms with response to AEDs in the Malaysian epilepsy patients and its three stratified populations by ethnicity. To examine this hypothesis, we analyzed alleles, genotypes, and haplotypes of three loci at the ABCB1 gene (C1236T, G2677T, and C3435T) and alleles and genotypes of one locus at the PXR (G7635A) gene. We found no association between ABCB1 C1236T, G2677T/A, and C3435T polymorphisms and their haplotypes with response to monotherapy with either CBZ or VPA in the total patients or in the Chinese, Indian and Malay subgroups following permutation test and Bonferroni's correction for multiple comparisons in haploype analysis. No confounding factor was proven that might affect the entire results of this association study. Overall, the findings of C3435T polymorphism were consistent with our meta-analysis for C3435T, but inconsistent with the original report. 8 The lack of association for the other two ABCB1
loci were compatible with all related studies of C1236T 9,16-24 but consistent with 9 previous studies 9, 16, [18] [19] [20] [22] [23] [24] 33 and inconsistent with 4 reports of on the G2677T locus. 10, 11, 17, 21 In this study, C1236 allele was less common than alternative allele in each ethnicity, similar to the previous reports from Asia. 9, [16] [17] [18] [19] [21] [22] [23] [24] Higher and lower frequencies of the G2677 allele than minor allele in the Chinese and Indian patients, respectively, were more similar to their original ancestors. 9, 16, 21, 22, 24 However, G2677 allele in the Malays was more frequent than alternative allele, consistent with the Chinese 16, 21 and Caucasian reports.
9,33
The C3435 allele was more common in all three ethnicities, similar to some Asian and Caucasian studies for the Chinese and Malays but different of original ancestry in the Indians. [8] [9] [10] [11] 33 Evidence suggested that the high ancient genetic variation in the human genome was lost during a severe bottleneck in the ancestors of Europeans when they emigrated from Africa. Emergence of Asians from Europe happened out of Africa. Despite of a common ancestor, frequencies of genetic polymorphisms varies between the Asians and Europeans. Since, prevalence of diseases varies among populations, so it is expected that the frequencies of genetic variants that contribute to their causation also vary. Geographic and cultural factors can cause genetic variation in different populations. This could be contributed by natural selection in a specific local environment. When two geographically separate populations are subject to distinct environmental or cultural pressure, positive selection may change the allele frequency in one population but not in another. [34] [35] [36] It is plausible that high variation of C3435T and G2677T polymorphisms among different epilepsy patient populations is caused by these two factors. We also analyzed the ABCB1 gene haplotypes derived from the C1236T, G2677T, and C3435T polymorphisms in the epilepsy Table 2 Genotypes and allele frequencies of ABCB1 and PXR polymorphisms of the drug-resistant (n = 323) and drug-responsive (n = 362) epilepsy patients and three ethnic subgroups.
Allele/genotype
Chinese (n = 277) Indian (n = 160) Malay (n = 248) Total (685)
ABCB1 C1236T C 113 (43) 122 (42) 59 (44) 84 (45) 111 (44) 95 (39) 283 (44) (21) 28 (19) 14 (21) 20 (22) 24 (18) 22 (18) 65 (20) 70 (19) CT 59 (45) 66 (45) 31 (46) 44 (47) 63 (46) 51 (41) 153 (47) 161 (45) TT 45 (34) 52 (36) 22 (33) 29 (31) 38 (36) 50 (41) 105 (33) 131 (36) ABCB1 G2677T G 144 (55) 144 (49) 49 (37) 84 (45) 138 (55) 125 (51) 331 (51) 353 (49) T 118 (45) 148 (51) 85 (63) 102 (55) 112 (45) 121 (49) 315 (49) 371 (51) GG 36 (27) 35 (24) 8 (12) 18 (19) 39 (31) 25 (20) 83 (26) 78 (22) GT 72 (55) 74 (51) 33 (49) 48 (52) 60 (48) 75 (61) 165 (51) 197 (54) TT 23 (18) 37 (25) 26 (39) 27 (29) 26 (21) 23 (19) 75 (23) 87 (24) (44) 125 (43) 56 (42) 97 (52) 99 (40) 102 (42) 270 (42) 324 (45) CC 39 (30) 49 (34) 23 (34) 17 (18) 47 (38) 44 (36) 109 (34) 110 (30) CT 69 (53) 69 (47) 32 (48) 55 (59) 57 (46) 56 (45) 158 (49) 180 (50) TT 23 (18) 28 (19) 12 (18) 21 (23) 21 (17) 23 (19) 56 (17) 72 (20) (42) 112 (38) 60 (45) 85 (46) 91 (36) 82 (33) 261 (40) 279 (39) GG 40 (30) 53 (36) 21 (31) 25 (27) 53 (42) 51 (42) 114 (35) (15) 19 (13) 14 (21) 17 (18) 19 (15) 10 (8) 52 (16) 46 (13) Abbreviations: NR, drug-resistance; R, drug-responsive.
Table 3
Genotypes and allele frequencies of ABCB1 and PXR polymorphisms in drug-resistant (n = 323) and drug-responsive (n = 362) epilepsy patients in the overall population studied and in the three ethnic subgroups under alternative genetic models.
Genotype Ethnicity
Chinese (n = 277) Indian (n = 160) Malay (n = 248) Total (685) 12 Chinese, 16 and Korean 23 studies.
In these three studies, CGC was more common than other haplotypes. We did not see any strong pairwise LD between the C1236T-G2677T/A, G2677T/A-C3435T, and C1236T-C3435T polymorphisms. Our data was comparable with Austrian 12 and Chinese patients 16 but for C1236T-G2677T/A polymorphisms in an Indian study. 9 High variation of pairwise LD in the ABCB1 gene and C3435T loci frequency among different populations in the previous reports could be referred to the proximity of this variant to the first hotspot of ABCB1 gene (Fig. 1) where crossing over happens. Accordingly, crossing over events in this hotspot not only may be involved with high variation of C3435T locus but also location of this hotspot may vary among the patient populations of the studies in epilepsy. We examined the association between PXR polymorphism with response to treatment in epilepsy, because it is reported being a regulator of expression of the ABCB1 gene. 37 A previous study failed to show any association between PXR 11156 A > C and 11193 T > C polymorphisms with response to AEDs treatment in Chinese epilepsy patients. 19 We selected PXR G7635A polymorphism to examine the association of this locus with response to AEDs in epilepsy because of three positive reports. One study showed a strong association between this polymorphism with susceptibility to inflammatory bowel disease and Crohn's disease. 26 Moreover, other two studies was performed in the renal transplant recipients who received cyclosporine or prednisolone. These studies demonstrated that the carriers of single G7635 allele or in LD with other alleles of PXR polymorphisms had lower plasma concentration of these drugs than noncarriers due to higher metabolic activity in the intestine. 27, 28 In contrast, our results did not verify the role of this locus in epilepsy suggesting that the G7635A polymorphism may not contribute to response to AEDs in Malaysian epilepsy patients. There is inconsistency between the results of previous association studies of some common polymorphisms of ABCB1 gene including C3435T with response to AEDs. A majority of these reports used polytherapy (86%). [8] [9] [10] [11] Drug interaction or their competition for interaction with common transporters, targets and metabolic mediators might be a plausible confounder factor in these studies. For example, VPA interacts with CBZ, LTG, and phenytoin. 38 Therefore, we stringently selected 42% of all epilepsy patients who were on monotherapy to have a homogenous population and obtain more reliable data. We focused more on VPA and CBZ monotherapy as an inclusion criterion, since these drugs are a widely used in epilepsy with a broad spectrum of activity. 39 However, inclusion of this criterion in the study caused smaller sample size than that in previous studies of subjects receiving polytherapy but still much larger than other similar studies in epilepsy patients on monotherapy. This gives a clearer picture of the association study with more reliable data. Furthermore, we applied adjusted ORs strategy for different variables including drug type to minimize their effects on the association study. Some reports suggested that CBZ and VPA are not substrates of P-gp. 40, 41 We examined this hypothesis by using a homogenous epilepsy population who are on either CBZ or VPA monotherapy treatment. Thus, the present study that shows negative results of the association of ABCB1 and PXR polymorphisms with drug response, as well as their interaction, supported this hypothesis that these two AEDs may not contribute to ABCB1. However, this finding was inconsistent with a positive study (37.1%) of the Table 4 Haplotype frequency of ABCB1 C1236T, G2677T/A, and C3435T polymorphisms within drug-resistant (n = 323) and drug-responsive (n = 362) epilepsy patients in the overall population studied and in the three ethnic subgroups. Haplotypes OR estimated odds ratio by binary logistic regression analysis adjusted for age at study, onset age at epilepsy, etiology, ethnicity, gender, drug type, and seizure type. Haplotypes with total frequencies over total patients below 5%.
* After using 100,000 permutation test and Bonferroni's correction for multiple comparisons for the Indians and Malays, these two significant associations were lost (p = 0.01 and p = 0.02 < 0.05/8, respectively).
patients who were on CBZ monotherapy, while in studies in which the patients were on polytherapy, VPA was commonly included (53.8%). 17 In contrast, VPA (35.8%) and CBZ (24.3%) one negative study, 42 or VPA (43.6%) in another one, 43 were the most commonly used drug in the polypharmacy treatment. The rest of the studies in which patients were on polytherapy did not report a clear history of AEDs in polypharmacy regimen of the patients. Our findings suggest that although CBZ or VPA may induce P-gp expression and function, this effect may indirectly contribute through other mediators or in connection of these genes with other genes and loci. [43] [44] [45] Further studies are necessary to find the probable link between these genes and other genes or loci with response to VPA and CBZ.
In conclusion, this study failed to show any association between the ABCB1 (C1236T, G2677T, and C3435T) and PXR (G7635A) polymorphisms with response to monotherapy with either CBZ or VPA in either the overall Malaysian epilepsy patients studied or in the ethnic subgroups. Our findings suggest that these loci may not contribute to response to drug treatment in epilepsy.
